| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.8 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |